Name: Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (Miniantibody)
SKU: MNAB-008
Rating: 5 (1 reviews)

Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (Miniantibody) is a fusion protein of two scFv fragments combined with distinct specificity. One scFv of an anti-Ang2 antibody variable domain is linked to another scFv of an anti-VEGFA antibody variable domain by a flexible hinge region. This BsAb format has the decreased size and better penetration than conventional IgGs in the clinical diagnostics and potentially therapy. This BsAb is capable of inhibiting two proangiogenics fators and a combined blockade of them has a greater inhibitory efficacy compared with inhibition of either factor alone. It is designed for the research of Colorectal cancer (CRC); Solid tumors; Wet AMD (Age-related macular degeneration); Diabetic macular edema therapy.

Datasheet INQUIRY

Specifications

Targets

Ang2 & VEGFA

Type

Miniantibody

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colorectal cancer (CRC); Solid tumors; Wet AMD (Age-related macular degeneration); Diabetic macular edema

Host Animal 1

Mouse

Host Animal 2

Mouse

Targets

Target 1

Ang2

Gene ID

285

UniProt ID

O15123

Alternative Names

ANGPT2; Ang2; angiopoietin 2; ANG2; AGPT2; angiopoietin-2; ANG-2; Tie2-ligand; angiopoietin-2B; angiopoietin-2a

Target 2

VEGFA

Gene ID

7422

UniProt ID

P15692

Alternative Names

VEGFA; vascular endothelial growth factor A; VPF; VEGF; MVCD1; vascular permeability factor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (Miniantibody) (MNAB-008). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-Ang2 x Anti-VEGFA Bispecific Antibody (Miniantibody) (CAT#: MNAB-008)

Specifications

Targets

Customer Reviews and Q&As